Moving engineered organotypic models towards the clinic
Cell-based assays for the prediction of patient-specific cancer response have not been widely adopted. However, it is timely to reevaluate their use, as numerous innovations, including micro-scale organ-on-a-chip models, may improve their predictive power and utility. We are exploring how different levels of organotypic complexity may be leveraged to recapitulate patient response in different disease states. And the tradeoffs between the model constraints for clinical use vs. mechanistic studies.